Inventor · disambiguated record
Saskia Maria Brachmann
Also filed as: BRACHMANN SASKIA MARIA
1 granted patent·8 pending applications·13 citations·filing 2008–2022
36Inventor score
Top patents by PatentIndex Score
9 records- 0183US9370508B2Imidazoquinolines as dual lipid kinase and mTOR inhibitorsGARCIA-ECHEVERRIA CARLOS·Filed 2008·Granted Jun 21, 2016·13 cites·1 claims
- 0259US2024317721A1Pyrazolyl derivatives as inhibitors of the kras mutant proteinNOVARTIS AG·Filed 2022·Application pending·0 cites
- 0357US2020022967A1Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family membersNOVARTIS AG·Filed 2019·Application pending·0 cites
- 0456US2024366567A1Pharmaceutical combinations comprising a kras g12c inhibitor and uses thereof for the treatment of cancersNOVARTIS AG·Filed 2022·Application pending·0 cites
- 0555US2018325883A1Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family membersNOVARTIS AG·Filed 2018·Application pending·0 cites
- 0653US2024082218A1Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor for the treatment of cancersNOVARTIS AG·Filed 2021·Application pending·0 cites
- 0748US2013209461A1Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family membersBRACHMANN SASKIA MARIA·Filed 2011·Application pending·0 cites
- 0844US2015250778A1Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family membersBRACHMANN SASKIA MARIA·Filed 2015·Application pending·0 cites
- 0936US2022152026A1Pharmaceutical combination comprising tno155 and a krasg12c inhibitorNOVARTIS AG·Filed 2020·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →